Abiraterone Acetate

證據等級: L5

預測適應症: 0 個

Abiraterone Acetate: Evidence Pack Incomplete — Evaluation on Hold

One-Sentence Summary

Abiraterone Acetate is a drug identified for drug repurposing evaluation, but the current Evidence Pack contains no predicted indications, no regulatory registration data, and no safety information. Without predicted indication targets or supporting evidence, a substantive repurposing evaluation cannot be conducted at this stage.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	None — TxGNN prediction results not included
TxGNN Prediction Score	Not available
Evidence Level	L5 (Model prediction only — no actual studies retrievable)
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (flagged as Data Gap DG002). No original indications have been recorded, and no TxGNN predicted indication has been returned in the predicted_indications field.

A DrugBank query was executed on 2026-03-26 and returned one result (result_count: 1), indicating that DrugBank data for this compound does exist and can be retrieved. However, the MOA and pharmacological category data were not successfully populated into the Evidence Pack. This should be the first priority for remediation.

Without MOA data, it is not possible to establish a mechanistic rationale connecting Abiraterone Acetate to any new indication, nor to assess pharmacological plausibility for repurposing.

Clinical Trial Evidence

Currently no related clinical trials registered under any predicted indication (no predicted indications available in this Evidence Pack).

Literature Evidence

Currently no related literature available (no predicted indications available to anchor a literature search).

Singapore Market Information

Abiraterone Acetate has 0 registered products in Singapore. No license records are available in this Evidence Pack.

Safety Considerations

Please refer to the package insert for safety information.

No safety data is available in this Evidence Pack:

Key warnings: not populated
Contraindications: not populated
Drug-drug interactions: query returned no results (DDI source query on 2026-03-26, result_status: not_found)

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Abiraterone Acetate is incomplete at multiple critical levels — no predicted indications, no MOA, no regulatory data, and no safety information — making it impossible to conduct a meaningful repurposing evaluation at this time.

To proceed, the following is needed:

Resolve DG001 (Blocking): Retrieve prescribing information / package insert warnings and contraindications from the regulatory authority website to enable safety pre-screening
Resolve DG002 (High): Query DrugBank API to populate MOA, pharmacological categories, and drug targets — the DrugBank query already returned 1 result and should be parsed
Re-run TxGNN pipeline: Ensure the prediction pipeline completes and populates predicted_indications before re-evaluation
Verify Singapore registration search: Confirm whether Abiraterone Acetate is marketed under any brand name (e.g., Zytiga) in Singapore and update taiwan_regulatory
Re-run DDI query: Current DDI result is not_found; verify whether drug name normalisation or alternate spellings (e.g., "abiraterone") are needed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.